Rash with Different Types of BCR-ABL Inhibitors in Chronic Myelogenous Leukemia: A Systematic Review and Meta-Analysis
Objective: A meta-analysis was conducted to systematically review the risks of all-grade as well as high-grade rash in chronic myelogenous leukemia (CML) patients using different types of BCR-ABL inhibitors. Methods: Literature published between 2000 and April 2022 were searched using PubMed, Cochrane Library, Embase and ClinicalTrials.gov. Results: A total of 12 studies were included for meta-analysis. The results showed that the incidence of all-grade or high-grade rash associated with new-generation BCR-ABL inhibitors had no significant difference compared with a standard dose of imatinib. Subgroup analysis suggested that, compared with imatinib, the incidence of all grades of rash was higher in the nilotinib, bosutinib and ponatinib groups. Conclusion: For CML patients treated with nilotinib, bosutinib and ponatinib, the occurrence of skin toxicity should not be ignored.
Authors
- Tingwen Wang
- Shuqi Dai (ORCID: https://orcid.org/0000-0002-3124-2681)
- Yu Zhong
- Su Li
Publication Details
- Journal
- Figshare
- Published
- 2026-11-13
- DOI
- https://doi.org/10.6084/m9.figshare.35003828
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00